Compare GFAI & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFAI | OSRH |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 18.4M |
| IPO Year | N/A | N/A |
| Metric | GFAI | OSRH |
|---|---|---|
| Price | $0.59 | $0.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 341.8K | ★ 2.6M |
| Earning Date | 09-23-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,987,715.00 | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.38 | N/A |
| 52 Week Low | $0.54 | $0.45 |
| 52 Week High | $2.20 | $12.54 |
| Indicator | GFAI | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 58.22 |
| Support Level | $0.60 | $0.68 |
| Resistance Level | $0.80 | $0.81 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 31.39 | 68.93 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.